Loading...
XKRX
001360
Market cap87mUSD
Dec 05, Last price  
1,364.00KRW
1D
1.49%
1Q
-16.88%
Jan 2017
-64.37%
Name

Samsung Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:001360 chart
P/E
—
P/S
2.90
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.80%
Rev. gr., 5y
-0.12%
Revenues
44.29b
-14.75%
32,802,727,00033,236,504,00037,057,787,00039,243,911,00044,078,652,92047,285,858,94046,920,574,89030,287,781,51042,164,637,26048,223,429,86041,919,468,82046,483,649,02044,566,363,21048,269,172,24054,901,130,22051,832,233,85051,955,037,96044,294,231,000
Net income
-14.09b
L-43.20%
-2,356,850,000634,209,0001,316,511,000-906,230,000-1,748,024,980-3,132,252,050-18,488,789,520-23,748,181,000-994,386,000-21,617,603,000-7,539,887,910-2,075,705,8306,885,173,790-63,764,012,920-62,678,093,540-36,953,663,440-24,812,021,760-14,092,018,000
CFO
-17.30b
L-37.47%
-1,492,388,0001,080,371,000-3,653,848,000-4,269,383,000-1,647,520,000-11,126,576,090603,654,480-13,583,335,010-4,204,949,290-9,941,381,0805,539,090,000-6,520,527,840-2,434,316,720-2,553,234,930-7,162,788,010-1,914,279,990-27,657,307,943-17,295,021,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.
URL
https://www.sspharm.co.kr/new/main/main.php
IPO date
Jul 04, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT